-
Parts of Germany's Rhine could become unnavigable, group warns
-
Days of heavy rain leave at least 13 dead in Philippines
-
Base Markets Appoints Nazim Moussaoui as Head of Premium Clients and Partnerships
-
Ex-Thai MP shoots dead local official over money row
-
US, South Korea to drill for new threats from North
-
July was Spain's hottest month on record: weather agency
-
SCANDIC TRADE Ultimate 2.6 är färdigutvecklat – SNC SCANDIC ECO-Systemet är nu komplett
-
SCANDIC TRADE Ultimate 2.6 je hotový – systém SNC SCANDIC ECO je kompletní
-
SCANDIC TRADE Ultimate 2.6 jest gotowy – system SNC SCANDIC ECO jest kompletny
-
تم الانتهاء من تطوير SCANDIC TRADE Ultimate 2.6 – وبذلك أصبح نظام SNC SCANDIC ECO متكاملاً
-
स्कैंडिक ट्रेड अल्टीमेट 2.6 अब पूरा हो गया है – SNC स्कैंडिक इको-सिस्टम अब पूरी तरह से चालू है।
-
SCANDIC TRADE Ultimate 2.6が完成――SNC SCANDIC ECOシステムが完成しました
-
Record July heat in regions home to 900 mn people: AFP analysis
-
Embattled Infantino target of letter from three confederations
-
SCANDIC TRADE Ultimate 2.6이 완성되었습니다 – SNC SCANDIC ECO-시스템이 완성되었습니다
-
SCANDIC TRADE Ultimate 2.6 已正式推出——SNC SCANDIC ECO 系統現已完整建置
-
SCANDIC TRADE Ultimate 2.6 завершено — екосистема SNC SCANDIC стала повноцінною
-
SCANDIC TRADE Ultimate 2.6 завершена — экосистема SNC SCANDIC стала полноценной
-
SCANDIC TRADE Ultimate 2.6 is now complete – the SNC SCANDIC ECO-System is now fully operational
-
Eighth day of wildfires in Indonesian national park
-
Chinese AI drives price competition among US labs
-
One woman confirmed dead in western Canada wildfire
-
Indian students step up exam protests in Jharkhand
-
Energy transition threatens to wipe Dutch village from map
-
Stopped broadcast, layoffs: Hungary media eyes post-Orban renewal
-
Self-taught Turkish 'linguist' keeps dead language alive
-
Typhoon Dolphin weakens but disrupts travel in east China
-
Asian stocks track Wall St higher after US job losses ease rate fears
-
Pakistan brickmakers scorched by sun above and fire below
-
Western Europe experienced hottest June-July on record: EU monitor
-
Ithaca bets on hometown hero Odysseus for tourism boom
-
Shelton sweeps Fonseca to reach Montreal quarter-final
-
Five things to know about Zambia ahead of the presidential vote
-
Who are the main contenders in Zambia's presidential vote?
-
Zambia vote to test Hichilema's economic record
-
Rybakina survives scare as Gauff, Osaka race into Toronto quarters
-
Meta will soon face another high-stakes trial in US
-
Thirty years on, a trial finally opens in Tupac Shakur's killing
-
Syria says reached deal with Moscow on fate of Russian bases
-
Shelton sweeps Fonseca to reach another Montreal quarter-final
-
Netanyahu rejects Gaza plan in new break from Trump
-
NioCorp to Host Webcast on Aug. 11 to Discuss Elk Creek Feasibility Study Results
-
Eco Minerals Announces Procurement of Kongsberg HUGIN Superior Autonomous Underwater Vehicle
-
Azarga Metals Mobilizes Drill Rig and Ancillary Equipment to Marg Project, Yukon
-
XCF Highlights Renewable Fuel Credit Market Strength, With Recent D4 RIN Values Representing More Than $3.50 Per Gallon
-
GEE Group to Hold Investor Conference Call to Discuss 2026 Fiscal Third Quarter Results
-
Caledonia Mining Corporation PLC: Results for the Quarter and Half Year Ended June 30, 2026; Details of Management Conference Call; Dividend Declaration
-
New Hampshire Shores Trust Expands CFSI's Advisor-Friendly Trust Services Capabilities
-
ABL Ascend Advanced Therapies Names Suman Subramanian as Chief Business Officer
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - August 10
'Very ignorant rumour': Misinformation abounds about monkeypox
The recent emergence of hundreds of cases of monkeypox worldwide has already triggered a flood of misinformation online, much of it modelled on conspiracy theories that have been circulating since the start of the Covid-19 pandemic.
AFP Fact Check examined three claims that have arisen in the month since monkeypox cases began being recorded outside of areas in western and central Africa where it is endemic.
- Not a vaccine side effect -
Social media posts shared across the world have incorrectly claimed that the recent monkeypox cases are a "side effect" of the AstraZeneca Covid-19 vaccine.
The claim is linked to the fact that AstraZeneca's jab uses a chimpanzee adenovirus vector.
But health experts told AFP that this idea "has no basis in fact", in part because the viruses belong in different families -- poxvirus for monkeypox, and adenovirus for the Covid vaccine.
The vaccine "cannot generate new viruses inside humans and cause something like monkeypox," said Professor Eom Jung-shik, an infectious disease expert at the Gachon University Gil Medical Center.
The adenovirus is the vaccine vector, which means it is only a vehicle to transport genetic instructions to the body to trigger the production of a spike protein similar to that of the SARS-CoV-2 virus. This then prompts an immune response so the body can fight a real infection.
As in other viral vector vaccines, the chimpanzee adenovirus has been altered so it does not infect humans or replicate.
Professor Yoo Jin-hong, an epidemiologist at the Catholic University of Korea, said the AstraZeneca claim "appears to stem from the idea that chimpanzees are broadly referred to as monkeys, but this is a very ignorant rumour with no basis in fact".
Monkeypox was given its name because it was first discovered in a group of macaques in 1958 that were being studied for research purposes, but they are not the only animals that catch the disease.
Rodents are the most likely natural reservoir of monkeypox, according to the World Health Organization.
- Pfizer does not have a monkeypox vaccine -
Social media posts have also claimed that the US Food and Drug Administration (FDA) recently approved a new monkeypox vaccine from pharma giant Pfizer, which developed the first available Covid vaccine.
This is false; the only vaccine for the prevention of monkeypox in the United States was approved by the FDA in 2019, and Pfizer does not manufacture it.
Abby Capobianco, a press officer at the FDA, told AFP that the vaccine, called Jynneos, was "licensed by FDA for the prevention of smallpox and monkeypox disease in adults 18 years of age and older determined to be at high risk for smallpox or monkeypox disease."
Jynneos is not a new vaccine -- the FDA approved it in September 2019.
Pharmaceutical company Bavarian Nordic, which produces Jynneos, announced on May 18, 2022 that the US government had placed a $119 million order for freeze-dried doses.
Jynneos is the only FDA-approved vaccine for monkeypox, however data has shown that a smallpox vaccine is 85 percent effective in preventing the disease, according to the US Centers for Disease Control and Prevention.
Pfizer told AFP that the company does not have a monkeypox vaccine.
- False Canada shingles claim -
Social media posts shared an image of a purported article from Canada's CTV News claiming that 95 percent of the monkeypox cases investigated by Canadian officials turned out to be shingles.
However Rob Duffy, CTV News manager of communications at its parent company Bell Media, told AFP that the network "never published such a story and that the screenshot does not show an authentic article from CTV News".
While some symptoms might be similar in cases of shingles and monkeypox, they are not caused by the same virus, according to Isaac Bogoch, professor at the Temerty Faculty of Medicine at the University of Toronto.
"There may be some overlap in their clinical presentation," but "monkeypox and shingles are two completely different infections," he told AFP.
O.Norris--AMWN